Properdin (factor P) as a new target cleaved by factor Xla: Intrinsic coagulation at the crossroads with inflammation

Qi Luo MSc1,2 | Philip Wenzel MD1,2,3,4

1Center for Thrombosis and Hemostasis Mainz, University Medical Center Mainz, Mainz, Germany
2Department of Biochemistry, CARIM School for Cardiovascular Research, Maastricht University, Maastricht, The Netherlands
3Center for Cardiology, Cardiology I, University Medical Center Mainz, Mainz, Germany
4DZHK (German Center for Cardiovascular Research), Partner Site Rhine Main, University Medical Center Mainz, Mainz, Germany

Correspondence
Philip Wenzel, Department of Cardiology and Center for Thrombosis and Hemostasis, Langenbeckstrasse 1, 55131 Mainz, Germany.
Email: wenzelp@uni-mainz.de

Handling Editor: Dr Henri Spronk

Keywords: commentary, factor XI, thrombosis

The complement system and blood coagulation cascade, in particular, the contact activation pathway, are functionally related and exhibit crossover activities. Deficiency or altered function of complement proteins are associated with thrombo-inflammatory diseases. Factor XI (FXI), as part of the intrinsic pathway, is the zymogen, which can be activated to the plasma protease FXIa by FXIIa with the help of high molecular weight kininogen, and then continue to the down-stream cascade of proteases that ultimately triggers the production of thrombin (FIIa). In addition to FXIIa, FXI can be feedback activated by thrombin, but also by autoactivation in the presence of surfaces such as sulfatides and glycosaminoglycans.1 In past decades, multiple studies have tried to clarify the role of FXI in thrombin generation and its relationship to contact activation.

Patients with FXI deficiency rarely have spontaneous bleeding; even with trauma to susceptible tissues or major surgery, bleeding is mostly moderate, indicating that FXI has a limited role in hemostasis. Interestingly, there is emerging evidence from epidemiologic data, animal models experiments, and human clinical trials indicating that FXI has a more important role in thromboembolic disease. FXI−/− mice had normal tail bleeding time but exhibited attenuated clot formation at the sites of arterial or venous injury.2 Likewise, treatment with FXI antisense oligonucleotides (FXI-ASO) or anti-FXI antibodies in rodent or rabbit models had shown resistance to experimentally induced thrombosis and a low risk of bleeding complications.3 Epidemiological studies showed that patients with lower levels of FXI are at reduced risk of venous thromboembolism (VTE) and cardiovascular diseases such as stroke, transient ischemic attack (TIA), and myocardial infarction (MI).4 Obviously, FXI is not involved in initiating thrombus formation, but rather contributes to the thrombus stabilization and growth through the amplification loop of thrombin feedback-activating FXI. This makes FXI(a) an attractive target for antithrombotic therapy. Novel FXI/FXIa inhibitor agents include inhibitors of biosynthesis, antibodies, and small molecules and are under development in clinical trials:

- Antisense oligonucleotides: FXI-ASO downregulates the FXI level by inhibiting its biosynthesis in liver. In a phase 2 study (NCT01713361), the FXI ASO IONIS-FXI-RX (200 mg or 300 mg) was compared with enoxaparin (40 mg) for prevention of VTE in patients undergoing total knee arthroplasty (TKA). The study showed that the higher dose (300 mg) regimen (4%) was superior to enoxaparin (30%) for the prevention of VTE and had lower bleeding events than with enoxaparin (3% vs. 8%). Therefore, this trial demonstrated that factor XI contributes to postoperative VTE and that lowering factor XI levels was an effective method for its prevention and appeared to be safe.5

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).
Abelacimab (MAA868) is a fully human, inhibitory FXI antibody that binds the catalytic domain of both FXI (zymogen) and active FXIa. One of three regimens of abelacimab (30, 75, or 150 mg) administered postoperatively in a single intravenous dose was compared with 40 mg of enoxaparin administered subcutaneously once in 412 patients who were undergoing TKA.6 Another trial comparing abelacimab (120, 180 mg) with placebo in patients with AF who are at low risk of thromboembolism (NCT04213807) is ongoing.

Oscimab (BAY 1213790) is a long-acting, fully human monoclonal antibody that inhibits factor Xla. A total of 813 adult patients who were undergoing TKA were involved in this phase 2 noninferiority study (FOXTROT). Oscimab (0.6, 1.2, and 1.8 mg/kg) was compared with enoxaparin and apixaban for thromboprophylaxis.5 Another trial is a 6-month study comparing subcutaneous osocimab at low or high doses with placebo in patients with end-stage renal disease undergoing hemodialysis is under way (NCT04523220). It is designed primarily to evaluate safety and the rates of the composite of major and clinically relevant nonmajor bleeding.

Milvexian (BMS-986177/NJU-70033093) is an oral small molecule, active-site inhibitor of FXIa. A phase 2 trial compared milvexian with enoxaparin for postoperative thromboprophylaxis in 1242 patients undergoing TKA (AXIOMATIC-TKR). Twice daily doses of milvexian ranging from 25 to 200 mg and once daily doses of 25, 50, or 100 mg were evaluated in patients undergoing knee arthroplasty, showing dose-dependent anticoagulation without significantly increasing the risk of bleeding.6 The recently presented results of the phase 2 trial AXIOMATIC-SSP (NCT03766581) indicate that milvexian did not reduce the composite of covert brain infarction or ischemic stroke at 90 days compared with placebo in patients with ischemic stroke or TIA on a background of antiplatelet therapy.

Asundexian (BAY 2433334): An oral chemically synthesized small molecule that binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits FXIa activity. In a phase 2 dose-finding clinical trial for the indication stroke prevention in atrial fibrillation, asundexian at doses of 20 mg and 50 mg once daily resulted in near-complete in vivo FXIa inhibition and in lower rates of bleeding compared with standard dosing of the active comparator, the FXa inhibitor apixaban.9 Two more phase 2 clinical trials investigating asundexian in acute MI or noncardioembolic stroke are completed: PACIFIC AMI10 and PACIFIC Stroke,11 both demonstrating no significant increase in bleeding when added to antiplatelet therapy.

The clinical potential of FXI/FXIa-directed anticoagulant strategies are further evaluated in phase 3 clinical trials in atrial fibrillation and stroke and represent an exciting new era in anticoagulation. In this issue of RPTH, Heal et al. used the methods of surface plasmon resonance, substrate specificity analysis, and enzyme kinetics analysis to demonstrate that properdin (Factor P), an intrinsic activator of the alternative complement pathway, is cleaved by activated coagulation FXIa, binds with high affinity to FXI/FXIa and modulates FXIa activity with downstream functional consequences. They further demonstrate a direct interaction between Factor P and FXI suggesting a novel crosslink of intrinsic coagulation and the activation of the alternative pathway of complement. This implies a broader understanding of thromboinflammatory events, and a putative off-target protection from inflammation-mediated (vascular) injury, as suggested by preclinical models of polymicrobial sepsis,12 or aggregation seen in a model of Streptococcus pneumoniae-induced sepsis.13 Factor P cleavage may outbalance the inhibitory effect of FXIa on complement Factor H, an intrinsic inhibitor of the alternative complement pathway.14 The discovery of properdin as target of FXIa adds to the list of even more off-target effectors of the protease FXI with implication in thromboinflammation, such as the adipokine and chemo-attractant chemerin15 and high molecular weight kininogen.16 These pleiotropic immune-modulatory sequelae of FXI-inhibition might explain, at least in part, the anti-inflammatory protection seen in models of atherosclerosis,17 arterial hypertension,18 and myocardial infarction.19 It remains to be established whether the activity of Factor P has potential implications for the FXIa-thrombin feedback activation, another important contributor to vascular inflammation. Future in vivo studies will be required to prove a pathophysiological role of the FXIa dependent properdin cleavage, and whether the cleavage products of Factor P will have pro- or anti-inflammatory properties in the vasculature.

AUTHOR CONTRIBUTION
Qi Luo drafted the manuscript, Philip Wenzel wrote the manuscript and handled funding and supervision.

FUNDING INFORMATION
P. W. was supported by a grant of the German Federal Ministry for Education and Research (BMBF 01EO1503) and the TICARDIO program, a Horizon2020 Marie Skłodowska-Curie Action (H2020-MSCA-ITN-2018; ID 813409).

RELATIONSHIP DISCLOSURE
Q. L. has no disclosures. P. W. reports serving as a consultant for Bayer and has received speaker honoraria from Bayer, Boehringer-Ingelheim, Pfizer, Daiichi Sankyo, Astra Zeneca, Abbot and Novartis.

TWITTER
Philip Wenzel @PhilipWenzel_76

REFERENCES
1. Gailani D, Broze GJ Jr. Factor XII-independent activation of factor XI in plasma: effects of sulfatides on tissue factor-induced coagulation. Blood. 1993;82:813-819.
2. Tillman BF, Gruber A, McCarty OJT, Gailani D. Plasma contact factors as therapeutic targets. Blood Rev. 2018;32:433-448.
3. Zhang H, Lowenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood. 2010;116:4684-4692.
4. Preis M, Hirsch J, Kotler A, et al. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood. 2017;129:1210-1215.
5. Buller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. *N Engl J Med*. 2015;372:232-240.

6. Verhamme P, Yi BA, Segers A, et al. Abelacimab for prevention of venous thromboembolism. *N Engl J Med*. 2021;385:609-617.

7. Weitz JI, Bauersachs R, Becker B, et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. *JAMA*. 2020;323:130-139.

8. Weitz JI, Strony J, Ageno W, et al. Milvexian for the prevention of venous thromboembolism. *N Engl J Med*. 2021;385:2161-2172.

9. Piccini JP, Caso V, Connolly SJ, et al. Safety of the oral factor Xa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. *Lancet*. 2022;399:1383-1390.

10. Rao SV, Kirsch B, Bhatt DL, et al. A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor Xa inhibitor Asundexian to prevent adverse cardiovascular outcomes following acute myocardial infarction. *Circulation*. 2022;146(16):1196-1206.

11. Shoamanesh A, Mund H, Smith EE, et al. Factor Xa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. *Lancet*. 2022;400:997-1007.

12. Tucker EI, Gailani D, Hurst S, Cheng Q, Hanson SR, Gruber A. Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis. *J Infect Dis*. 2008;198:271-274.

13. Stroo I, Zeerleder S, Ding C, et al. Coagulation factor X1 improves host defence during murine pneumonia-derived sepsis independent of factor XII activation. *Thromb Haemost*. 2017;117:1601-1614.

14. Puy C, Pang J, Reitsma SE, et al. Cross-talk between the complement pathway and the contact activation system of coagulation: activated factor XI neutralizes complement factor H. *J Immunol*. 2021;206:1784-1792.

15. Ge X, Yamaguchi Y, Zhao L, et al. Prochemerin cleavage by factor Xla links coagulation and inflammation. *Blood*. 2018;131:353-364.

16. Mauron T, Lammlle B, Wullemmin WA. High molecular weight kininogen is cleaved by FXIa at three sites: Arg409-Arg410, Lys502-Thr503 and Lys325-Lys326. *Thromb Haemost*. 2000;83:709-714.

17. Shnerb Ganor R, Harats D, Schiby G, et al. Factor XI deficiency protects against atherogenesis in apolipoprotein E/factor XI double knockout mice. *Arterioscler Thromb Vasc Biol*. 2016;36:475-481.

18. Kossmann S, Lagrange J, Jackel S, et al. Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension. *Sci Transl Med*. 2017;9:9.

19. Lorentz CU, Verbout NG, Cao Z, et al. Factor XI contributes to myocardial ischemia-reperfusion injury in mice. *Blood Adv*. 2018;2:85-88.

---

**How to cite this article:** Luo Q, Wenzel P. Properdin (factor P) as a new target cleaved by factor Xla: Intrinsic coagulation at the crossroads with inflammation. *Res Pract Thromb Haemost*. 2022;6:e12835. doi: [10.1002/rth2.12835](https://doi.org/10.1002/rth2.12835)